| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $5,844,183 | 2 | 4 |
Sells | $150,308,920 | 48 | 96 |
| Kewalramani Reshma | CEO & President | 1 | $3.9M | 1 | $19.74M | $-15.84M |
| SACHS BRUCE I | director | 1 | $1.95M | 0 | $0 | $1.95M |
| Bhatia Sangeeta N. | director | 0 | $0 | 3 | $438,204 | $-438,204 |
| Liu Joy | EVP and Chief Legal Officer | 0 | $0 | 1 | $442,396 | $-442,396 |
| Bozic Carmen | EVP and CMO | 0 | $0 | 1 | $1.12M | $-1.12M |
| Ambrose Kristen | SVP & Chief Accounting Officer | 0 | $0 | 5 | $1.98M | $-1.98M |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 0 | $0 | 4 | $2.98M | $-2.98M |
| ALTSHULER DAVID | EVP, Chief Scientific Officer | 0 | $0 | 3 | $3.29M | $-3.29M |
| McKechnie Duncan | EVP, Chief Commercial Officer | 0 | $0 | 2 | $3.55M | $-3.55M |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 0 | $0 | 5 | $3.6M | $-3.6M |
| Biller Jonathan | EVP and Chief Legal Officer | 0 | $0 | 7 | $4.08M | $-4.08M |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 0 | $0 | 8 | $7.35M | $-7.35M |
| WAGNER CHARLES F JR | EVP & Chief Financial Officer | 0 | $0 | 3 | $12.43M | $-12.43M |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 0 | $0 | 2 | $28.38M | $-28.38M |
| LEIDEN JEFFREY M | Executive Chairman | 0 | $0 | 3 | $60.94M | $-60.94M |
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Over the last 12 months, insiders at Vertex Pharmaceuticals Incorporated have bought $5.84M and sold $150.31M worth of Vertex Pharmaceuticals Incorporated stock.
On average, over the past 5 years, insiders at Vertex Pharmaceuticals Incorporated have bought $5.38M and sold $80.22M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kewalramani Reshma (CEO & President) — $3.9M. SACHS BRUCE I (director) — $1.95M.
The last purchase of 5,000 shares for transaction amount of $1.95M was made by SACHS BRUCE I (director) on 2025‑08‑06.
| 2026-03-04 | Sale | McKechnie Duncan | EVP, Chief Commercial Officer | 2,437 0.001% | $475.30 | $1.16M | -2.02% | |
| 2026-03-02 | Sale | Liu Joy | EVP and Chief Legal Officer | 892 0.0004% | $495.96 | $442,396 | -2.75% | |
| 2026-02-27 | Sale | Kewalramani Reshma | CEO & President | 40,000 0.0156% | $493.47 | $19.74M | -2.92% | |
| 2026-02-27 | Sale | Bozic Carmen | EVP and CMO | 2,329 0.0009% | $480.31 | $1.12M | -2.92% | |
| 2026-02-26 | Sale | Ambrose Kristen | SVP & Chief Accounting Officer | 357 0.0001% | $483.36 | $172,560 | -1.04% | |
| 2026-02-25 | Sale | Sachdev Amit | EVP Chief Patient & Ext Af Off | 1,846 0.0007% | $486.35 | $897,802 | -2.58% | |
| 2026-02-25 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 260 0.0001% | $486.35 | $126,451 | -2.58% | |
| 2026-02-25 | Sale | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 668 0.0003% | $486.35 | $324,882 | -2.58% | |
| 2026-02-25 | Sale | McKechnie Duncan | EVP, Chief Commercial Officer | 4,910 0.002% | $487.65 | $2.39M | -2.58% | |
| 2026-02-25 | Sale | Biller Jonathan | EVP and Chief Legal Officer | 945 0.0004% | $486.35 | $459,601 | -2.58% | |
| 2026-02-25 | Sale | Bunnage Mark E. | EVP, Chief Scientific Officer | 620 0.0002% | $486.35 | $301,537 | -2.58% | |
| 2026-02-25 | Sale | Ambrose Kristen | SVP & Chief Accounting Officer | 223 <0.0001% | $486.35 | $108,456 | -2.58% | |
| 2026-02-19 | Sale | Sachdev Amit | EVP Chief Patient & Ext Af Off | 58,613 0.023% | $468.83 | $27.48M | +2.38% | |
| 2026-02-18 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 368 0.0001% | $473.68 | $174,314 | +1.70% | |
| 2026-02-18 | Sale | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 817 0.0003% | $473.68 | $386,997 | +1.70% | |
| 2026-02-18 | Sale | Biller Jonathan | EVP and Chief Legal Officer | 1,244 0.0005% | $473.68 | $589,258 | +1.70% | |
| 2026-02-18 | Sale | Bunnage Mark E. | EVP, Chief Scientific Officer | 1,182 0.0005% | $473.68 | $559,890 | +1.70% | |
| 2026-02-18 | Sale | Ambrose Kristen | SVP & Chief Accounting Officer | 638 0.0003% | $473.68 | $302,208 | +1.70% | |
| 2026-02-17 | Sale | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 609 0.0002% | $489.46 | $298,081 | -2.38% | |
| 2026-02-17 | Sale | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 2,031 0.0008% | $489.46 | $994,093 | -2.38% |
| Kewalramani Reshma | CEO & President | 98278 0.0387% | $44.88M | 2 | 28 | +20.8% |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 55570 0.0219% | $25.38M | 1 | 105 | +5.21% |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 46763 0.0184% | $21.36M | 0 | 41 | |
| SACHS BRUCE I | director | 45000 0.0177% | $20.55M | 8 | 33 | +20.8% |
| WAGNER CHARLES F JR | EVP, CO & FO | 37725 0.0149% | $17.23M | 0 | 17 | |
| Bozic Carmen | EVP and CMO | 37734 0.0149% | $17.23M | 0 | 13 | |
| LEIDEN JEFFREY M | Executive Chairman | 24026 0.0095% | $10.97M | 2 | 55 | <0.0001% |
| ALTSHULER DAVID | EVP, Chief Scientific Officer | 23281 0.0092% | $10.63M | 0 | 93 | |
| Liu Joy | EVP and Chief Legal Officer | 22811 0.009% | $10.42M | 0 | 8 | |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 18432 0.0073% | $8.42M | 0 | 13 | |
| McKechnie Duncan | EVP, Chief Commercial Officer | 15122 0.006% | $6.91M | 0 | 2 | |
| Biller Jonathan | EVP and Chief Legal Officer | 13659 0.0054% | $6.24M | 0 | 12 | |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 7284 0.0029% | $3.33M | 0 | 4 | |
| Ambrose Kristen | SVP & Chief Accounting Officer | 6624 0.0026% | $3.03M | 0 | 14 | |
| Bhatia Sangeeta N. | director | 4299 0.0017% | $1.96M | 0 | 26 | |
| Vertex Pharmaceuticals (Europe) Ltd | 10 percent owner | 5380940 2.1185% | $2.46B | 4 | 0 | +14.31% |
| BOGER JOSHUA S | director | 268225 0.1056% | $122.5M | 0 | 371 | |
| Emmens Matthew | director | 200873 0.0791% | $91.74M | 0 | 3 | |
| MUELLER PETER | EVP, Global R&D, CSO | 143517 0.0565% | $65.54M | 0 | 67 | |
| ALAM JOHN J | EVP, Med. Dev. Group & CMO | 136792 0.0539% | $62.47M | 0 | 31 | |
| BOGER KENNETH S | SVP & Chief Legal Officer | 112999 0.0445% | $51.61M | 1 | 19 | +11.42% |
| SATO VICKI L | President | 108108 0.0426% | $49.37M | 0 | 74 | |
| Hartmann Victor A | EVP, Strategic & Corp. Devlp. | 97273 0.0383% | $44.42M | 0 | 10 | |
| Chodakewitz Jeffrey | EVP GMDA, CMO | 69663 0.0274% | $31.81M | 0 | 33 | |
| Graves Kurt | EVP, Chief Commercial Officer | 59880 0.0236% | $27.35M | 1 | 11 | +4.03% |
| Lewis-Hall Freda C | EVP, Medicines Development | 53334 0.021% | $24.36M | 0 | 4 | |
| Arbuckle Stuart A | EVP, COO | 49691 0.0196% | $22.69M | 0 | 101 | |
| SMITH IAN F | EVP, COO | 46699 0.0184% | $21.33M | 0 | 66 | |
| BRUM LYNNE H | VP, Strategic Communications | 46199 0.0182% | $21.1M | 0 | 18 | |
| Pace Megan E | SVP, Corp. Communications | 43350 0.0171% | $19.8M | 0 | 12 | |
| Stamoulis Christiana | SVP, Corp Strategy & Bus Devlp | 40712 0.016% | $18.59M | 0 | 5 | |
| GARRISON RICHARD C | SVP and Catalyst | 37473 0.0148% | $17.11M | 0 | 8 | |
| Connolly Thomas | SVP, Human Resources | 34375 0.0135% | $15.7M | 0 | 12 | |
| Horton Kenneth L | EVP & Chief Legal Officer | 32463 0.0128% | $14.83M | 0 | 4 | |
| Wysenski Nancy | EVP, Chief Commercial Officer | 32232 0.0127% | $14.72M | 0 | 6 | |
| Sanna Bastiano | EVP, Cell & Genetic Therapies | 32038 0.0126% | $14.63M | 0 | 23 | |
| Parini Michael | EVP, Chief Adm, Leg & BD Off | 30837 0.0121% | $14.08M | 0 | 63 | |
| SANDERS CHARLES A | director | 26383 0.0104% | $12.05M | 1 | 14 | +17.73% |
| Kelly Lisa | SVP, Human Resources | 15216 0.006% | $6.95M | 0 | 28 | |
| Graney Thomas | Chief Financial Officer | 12430 0.0049% | $5.68M | 0 | 2 | |
| CORDES EUGENE | director | 12000 0.0047% | $5.48M | 0 | 3 | |
| Silva Paul M | SVP & Chief Accounting Officer | 9884 0.0039% | $4.51M | 0 | 116 | |
| YOUNG WILLIAM D | director | 9311 0.0037% | $4.25M | 0 | 2 | |
| Howton David T | SVP | 9271 0.0037% | $4.23M | 0 | 1 | |
| POWER JOHANNA MESSINA | VP & Controller | 6555 0.0026% | $2.99M | 0 | 56 | |
| WINGER DENNIS L | director | 6500 0.0026% | $2.97M | 1 | 0 | <0.0001% |
| Kearney Terrence C | director | 6536 0.0026% | $2.98M | 0 | 4 | |
| ULLIAN ELAINE | director | 5265 0.0021% | $2.4M | 3 | 15 | +46.27% |
| CARNEY LLOYD | director | 4150 0.0016% | $1.9M | 0 | 1 | |
| COLLINSON STUART J | director | 3279 0.0013% | $1.5M | 0 | 7 | |
| BUCHANAN IAIN P M | VP, European Operations | 2094 0.0008% | $956,308.86 | 0 | 6 | |
| Lee Yuchun | director | 1875 0.0007% | $856,293.75 | 0 | 31 | |
| MCGLYNN MARGARET G | 1099 0.0004% | $501,902.31 | 1 | 12 | +64.37% | |
| Slater Eve Elizabeth | director | 1105 0.0004% | $504,642.45 | 2 | 1 | +1.76% |
| Riley Wayne Joseph | director | 400 0.0002% | $182,676.00 | 0 | 6 | |
| BRANDT ERIC | director | 0 0% | $0 | 0 | 1 | |
| BRIMBLECOMBE ROGER W | director | 0 0% | $0 | 0 | 6 |
$961,890,236 | 276 | 22.46% | $19.09B | |
$211,610,344 | 91 | 38.45% | $9.83B | |
$2,765,836 | 72 | 20.00% | $11.75B | |
$2,449,191,716 | 58 | 16.50% | $78.95B | |
$11,789,714 | 49 | 14.35% | $30.21B | |
$323,530,732 | 48 | 29.90% | $42.53B | |
$88,307,390 | 38 | -1.70% | $11.2B | |
$19,233,721 | 36 | 70.14% | $11.14B | |
$13,655,378 | 35 | 17.13% | $20.96B | |
Vertex Pharmaceuticals Incorporated (VRTX) | $15,836,193 | 25 | 17.98% | $116B |
$415,090,639 | 19 | -14.04% | $12.67B | |
$143,065,458 | 17 | 8.01% | $19.5B | |
$152,272,932 | 16 | -10.78% | $19.45B | |
$627,701,115 | 15 | 145.68% | $11.25B | |
$284,820 | 10 | 45.67% | $12.23B | |
$55,713,031 | 8 | -0.36% | $8.91B | |
$41,376,000 | 4 | -12.07% | $8.53B | |
$40,276,273 | 4 | 34.57% | $20.6B | |
$999,989 | 1 | 262.16% | $20.74B |
| Increased Positions | 882 | +54.65% | 13M | +5.59% |
| Decreased Positions | 697 | -43.18% | 13M | -5.5% |
| New Positions | 245 | New | 3M | New |
| Sold Out Positions | 108 | Sold Out | 2M | Sold Out |
| Total Postitions | 1,799 | +11.46% | 236M | +0.09% |
| Capital World Investors | $11.71M | 10.2% | 25.91M | -3M | -9.82% | 2025-09-30 |
| Vanguard Group Inc | $10.95M | 9.53% | 24.22M | +243,088 | +1.01% | 2025-09-30 |
| Blackrock, Inc. | $10.06M | 8.76% | 22.25M | +381,102 | +1.74% | 2025-09-30 |
| Capital Research Global Investors | $7.48M | 6.52% | 16.55M | +444,990 | +2.76% | 2025-09-30 |
| State Street Corp | $5.25M | 4.57% | 11.61M | -169,227 | -1.44% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.91M | 2.53% | 6.43M | +565,417 | +9.63% | 2025-09-30 |
| Geode Capital Management, Llc | $2.7M | 2.35% | 5.97M | +44,998 | +0.76% | 2025-09-30 |
| Wellington Management Group Llp | $2.16M | 1.88% | 4.77M | -41,344 | -0.86% | 2025-09-30 |
| Capital International Investors | $2.12M | 1.85% | 4.69M | +2M | +77.89% | 2025-09-30 |
| Alliancebernstein L.P. | $2.04M | 1.78% | 4.52M | +144,266 | +3.29% | 2025-09-30 |